Protagonist Therapeutics, Inc

Protagonist Therapeutics trades at a $6.4B valuation despite lacking profitability (n/a P/E), suggesting the market is pricing in substantial future clinical or commercial success. The 15.3% short interest is notably elevated for a biotech, indicating meaningful skepticism exists alongside bullish sentiment. With RSI at 53.3—right at neutral—the stock shows no technical extremes, and being off its 52-week highs leaves room for both upside rallies and potential reversals. The disconnect between current market cap and absent earnings implies this is purely a clinical-stage bet where pipeline progress or clinical trial results will be the primary stock drivers, making fundamental execution risk the dominant factor.